Handelsavisen
prelaunch
Companies Healthcare ZIMV.O
ZI
ZIMV.O NASDAQ Health Care Equipment & Supplies

ZimVie Inc

Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-2,1 %
ROE
-5,1 %
Net margin
-4,4 %
Debt / equity
0,58
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

ZimVie Inc operates in the Health Care Equipment & Supplies industry, generating revenue through the sale of dental and medical products.

Business. ZimVie Inc (ZIMV.O) is a health care equipment and supplies company that operates within the medical device industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. ZimVie is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability
-5,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ZIMV.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ZIMV.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ZimVie Inc (ZIMV.O) is a health care equipment and supplies company that operates within the medical device industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. ZimVie is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupHealth Care Equipment & Supplies
    AI synthesis
    GENERATED

    ZimVie maintains a capital structure characterized by moderate leverage and adequate short-term liquidity. The company holds total assets of $753.7 million against total liabilities of $372.0 million, resulting in total equity of $381.7 million. Long-term debt stands at $220.5 million, yielding a debt-to-equity ratio of 0.58. Liquidity is supported by a current ratio of 1.92, indicating sufficient current assets to cover current liabilities. However, the company reports negative net cash, as cash and equivalents of $75.0 million are insufficient to offset total debt obligations. Operating cash flow is positive at $14.2 million, but free cash flow is negative at -$6.2 million due to capital expenditures of $6.7 million.

    Profitability metrics indicate operational challenges in the latest period. The company reported revenue of $449.7 million and gross profit of $287.4 million, implying a gross margin of approximately 63.9%. Despite healthy gross margins, operating income is negative at -$20.7 million, leading to a net loss of -$25.8 million. Return on equity is -5.1%, and return on assets is -2.6%, reflecting the inability to generate positive returns on invested capital during this period. These figures suggest that operating expenses and interest costs are currently exceeding operating income.

    Segment and geographic data are not provided in the available input, preventing a detailed analysis of revenue concentration or regional exposure. The company’s business activity is broadly defined within the Health Care Equipment & Supplies sector, but specific product mix or customer concentration risks cannot be quantified from the current dataset.

    Growth trajectory analysis is limited by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to assess the direction or velocity of revenue growth or profitability improvement. The single-period snapshot shows a revenue base of $449.7 million, but year-over-year changes are not disclosed.

    Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility. The company has 28.2 million basic shares outstanding, with no difference between basic and diluted shares, suggesting minimal immediate dilution from options or convertible securities. The low dilution risk rating supports the stability of the current share count.

    Recent observations include an actual EPS of $0.62 and actual revenue of $449.7 million, which may reflect a prior period or adjusted figure given the current net loss. ESG metrics show a total score of 29.29 with a grade of C-, driven by a low environment pillar score of 13.13 and a governance score of 24.38, though the social pillar is higher at 38.73. The ESG controversies score is 100, indicating no significant controversies.

    Key takeaways
    • ZimVie reports a net loss of $25.8 million on revenue of $449.7 million, with negative operating income of $20.7 million.
    • The company has a debt-to-equity ratio of 0.58 and a current ratio of 1.92, indicating moderate leverage and adequate short-term liquidity.
    • Free cash flow is negative at -$6.2 million, despite positive operating cash flow of $14.2 million, due to capital expenditures.
    • Net cash is negative, as cash and equivalents of $75.0 million do not cover long-term debt of $220.5 million.
    • Dilution risk is assessed as low, with no difference between basic and diluted shares outstanding.
    • ESG performance is rated C- with a total score of 29.29, highlighting weaknesses in environmental and governance pillars.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2025-07-30
    Q2 2025 · Quarter highlights

    Revenue $116.7M, −0,1% YoY; Operating income +119,3% YoY.

    Revenue$116.7M−0,1 % YoY
    Operating income$1.3M+119,3 % YoY
    Net income-$3.9M+1,7 % YoY
    Free cash flow$3.2M+237,8 % YoY
    EPS
    Operating cash flow-$10.7M−26,0 % YoY
    Financials
    Income statement
    Revenue$116.7M
    Gross profit$75.3M
    Operating income$1.3M
    Net income-$3.9M
    Margins
    Gross margin64.6%
    Operating margin1.1%
    Net margin-3.4%
    FCF margin2.7%
    Balance sheet
    Total assets$758.2M
    Total liabilities$345.4M
    Total equity$412.8M
    Cash & equivalents$70.2M
    Long-term debt$220.8M
    Cash flow
    Operating cash flow-$10.7M
    CapEx-$3.1M
    Free cash flow$3.2M
    SBC
    P&L flow · revenue → net income
    Revenue $116.7MOperating costs $115.4MTax $5.2MNet income $3.9M
    Highlights
    • Revenue $116.7M, −0,1% YoY
    • Operating income +119,3% YoY
    • Net income +1,7% YoY
    • Free cash flow +237,8% YoY
    • Net margin -3.4%

    Valuation TTM

    Market price
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $381.7M
    Net cash
    -$145.5M
    Current ratio
    1.9
    Debt / equity
    0.6
    ROA
    -2.6%
    ROE
    -5.1%
    Cash conversion
    -73.0%
    CapEx / revenue
    -1.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-2,1 %Below median
    Net Margin-4,4 %Below median
    ROE-5,1 %Below median
    Capex / Rev-1,5 %Above median
    D/E0,58Below median
    Cash Conv-0,73Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Return On Assets
      net_income / total_assets
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    Source documents
    • ZimVie Inc Market data — financials · 2026-07-26
    • ZimVie Inc Market data — analyst estimates · 2026-07-26
    • ZimVie Inc Market data — ESG · 2026-07-26

    Ownership & reference

    Top holders

    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$33M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ZIMV.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2025-07-30 16:05 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 116.7M · Net USD -3.9M
    2025-05-08 16:05 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 112.0M · Net USD -1.5M
    2025-02-26 16:17 UTCEARNINGSQuarterly results — Q4 2024 Revenue USD 111.5M · Net USD -11.8M
    2025-02-26 16:17 UTCEARNINGSAnnual results — FY 2025 Revenue USD 449.7M · Net USD -25.8M
    2024-10-30 16:12 UTCEARNINGSQuarterly results — Q3 2024 Revenue USD 103.2M · Net USD -2.3M
    2024-08-01 16:05 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 116.8M · Net USD -4.0M
    2024-05-08 16:05 UTCEARNINGSQuarterly results — Q1 2024 Revenue USD 118.2M · Net USD -7.8M
    2024-02-28 17:35 UTCEARNINGSQuarterly results — Q4 2023
    2024-02-28 17:35 UTCEARNINGSAnnual results — FY 2024 Revenue USD 457.4M · Net USD -393.3M
    2023-11-01 16:07 UTCEARNINGSQuarterly results — Q3 2023 Revenue USD 105.3M · Net USD -5.1M
    2023-03-01 16:05 UTCEARNINGSAnnual results — FY 2023 Revenue USD 463.3M · Net USD -63.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage